FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Inyx, Inc. Stock AnalysisComprehensive stock analysis for Inyx, Inc. (IYXI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIYXI
IYXI
Inyx, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
IYXI
Home🔹Stocks🔹Inyx, Inc.

Inyx, Inc.

IYXI•OTC

Inyx, Inc.

IYXI•OTC
Market cap
$5.23K
Sentiment

Your view on IYXI

Mkt Cap
$5.23K
Sentiment
Your view
IYXI
Inyx, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
IYXI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Inyx, Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Steven Handley
Headquarters
825 Third Avenue, New York City, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Steven Handley
Headquarters
825 Third Avenue, New York City, US
Description

Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News